| Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease L Jostins, S Ripke, RK Weersma, RH Duerr, DP McGovern, KY Hui, ... Nature 491 (7422), 119-124, 2012 | 5460 | 2012 |
| Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies A Antoniou, PDP Pharoah, S Narod, HA Risch, JE Eyfjord, JL Hopper, ... American journal of human genetics 72 (5), 1117, 2003 | 4941 | 2003 |
| Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers KB Kuchenbaecker, JL Hopper, DR Barnes, KA Phillips, TM Mooij, ... Jama 317 (23), 2402-2416, 2017 | 3163 | 2017 |
| Dexamethasone in hospitalized patients with Covid-19 RECOVERY Collaborative Group New England Journal of Medicine 384 (8), 693-704, 2021 | 3010 | 2021 |
| Genome-wide association study identifies novel breast cancer susceptibility loci DF Easton, KA Pooley, AM Dunning, PDP Pharoah, D Thompson, ... Nature 447 (7148), 1087-1093, 2007 | 2863 | 2007 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 2301* | 2021 |
| Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations TR Rebbeck, HT Lynch, SL Neuhausen, SA Narod, L Van't Veer, ... New England Journal of Medicine 346 (21), 1616-1622, 2002 | 1904 | 2002 |
| Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality SM Domchek, TM Friebel, CF Singer, DG Evans, HT Lynch, C Isaacs, ... Jama 304 (9), 967-975, 2010 | 1763 | 2010 |
| Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group TR Rebbeck, T Friebel, HT Lynch, SL Neuhausen, L Van’t Veer, ... Journal of clinical oncology 22 (6), 1055-1062, 2004 | 1569 | 2004 |
| Malignant peripheral nerve sheath tumours in neurofibromatosis 1 DGR Evans, ME Baser, J McGaughran, S Sharif, E Howard, A Moran Journal of medical genetics 39 (5), 311-314, 2002 | 1462 | 2002 |
| Low-penetrance susceptibility to breast cancer due to CHEK2* 1100delC in noncarriers of BRCA1 or BRCA2 mutations H Meijers-Heijboer, A van den Ouweland, J Klijn, M Wasielewski, ... Nature genetics 31 (1), 55-59, 2002 | 1442 | 2002 |
| Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002) SR Cairns, JH Scholefield, RJ Steele, MG Dunlop, HJW Thomas, ... Gut 59 (5), 666-689, 2010 | 1369 | 2010 |
| Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). MO Leach, CR Boggis, AK Dixon, DF Easton, RA Eeles, DG Evans, ... Lancet 365 (9473), 1769, 2005 | 1326 | 2005 |
| Large-scale genotyping identifies 41 new loci associated with breast cancer risk K Michailidou, P Hall, A Gonzalez-Neira, M Ghoussaini, J Dennis, ... Nature genetics 45 (4), 353-361, 2013 | 1314 | 2013 |
| Guidelines for the diagnosis and management of individuals with neurofibromatosis 1 RE Ferner, SM Huson, N Thomas, C Moss, H Willshaw, DG Evans, ... Journal of medical genetics 44 (2), 81-88, 2007 | 1264 | 2007 |
| PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene N Rahman, S Seal, D Thompson, P Kelly, A Renwick, A Elliott, S Reid, ... Nature genetics 39 (2), 165-167, 2007 | 1237 | 2007 |
| Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial J Burn, AM Gerdes, F Macrae, JP Mecklin, G Moeslein, S Olschwang, ... The Lancet 378 (9809), 2081-2087, 2011 | 1173 | 2011 |
| Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE N Mavaddat, S Peock, D Frost, S Ellis, R Platte, E Fineberg, DG Evans, ... JNCI: Journal of the National Cancer Institute 105 (11), 812-822, 2013 | 1166 | 2013 |
| The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in … SR Lakhani, MJ Van De Vijver, J Jacquemier, TJ Anderson, PP Osin, ... Journal of clinical oncology 20 (9), 2310-2318, 2002 | 1145 | 2002 |
| The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women MN Harvie, M Pegington, MP Mattson, J Frystyk, B Dillon, G Evans, ... International journal of obesity 35 (5), 714-727, 2011 | 1130 | 2011 |
Anthony Howell, Howell A, Howell TProfessor of Medical Oncology, Manchester UniversityZweryfikowany adres z picr.man.ac.uk